Actuate Therapeutics, Inc. · NASDAQ:ACTU
Actuate Therapeutics — Investor Presentation (May 2026)
18 slides from Actuate Therapeutics's investor presentation, May 11, 2026
Slide 1: Corporate Overview May 11, 2026
Corporate Overview May 11, 2026
Slide 2: Forward-looking statements
This presentation contains forward - looking statements about us, including our clinical trials and development plans, and our industry, that are based on management’s beliefs and assumptions and on information currently available to our management . The words “anticipate,” “believe,” “continue,” “c
Slide 3: Elraglusib – Pipeline in a Molecule
2 Elraglusib – “Pipeline in a Molecule” Therapeutic Potential Across a Broad Range of Cancers Elraglusib is a class - leading GSK - 3 β inhibitor with a novel, multimodal MOA Clinical trials in 500+ patients resulted in complete responses and significant increases in survival in multiple difficult -
Slide 4: Elraglusib Development Strategy
3 Elraglusib Development Strategy Develop Elraglusib Oral Tablet to expand portfolio • Initiate phase 1/2 trial to expand into additional high value / blockbuster indications Advance pathway to be the backbone of SOC in PDAC • Complete nonclinical research assessing potential synergy between elraglu
Slide 5: Elraglusib: Multimodal MOA Blocks Cancer Survival Pathways
4 Elraglusib: Multimodal MOA Blocks Cancer Survival Pathways Elraglusib targets cancer survival pathways ERK Dabrafenib Encorafenib Vemurafenib Trametinib Binimetinib Cobimetinib Avutometinib Sotorasib Adagrasib Daraxonrasib RAS RAF MEK Ulixertinib Cancer driver pathways NF - κB Cancer cell survival
Slide 6: Elraglusib Significantly Improves OS in a Most Difficult to Treat Cancer
5 Elraglusib Significantly Improves OS in a Most Difficult to Treat Cancer mPDAC: metastatic pancreatic ductal adenocarcinoma; GnP: Gemcitabine + Nab - paclitaxel; OS: Overall survival Survival Probability 0.0 1.0 0.8 0.6 0.4 0.2 Months 7.2 mos. 10.1 mos. 22.3% 12 - month OS 44.4% mOS GnP Elraglusib
Slide 7: Elraglusib Significantly Improves Survival with Weekly IV Dosing
6 Elraglusib Significantly Improves Survival with Weekly IV Dosing Randomized Phase 2 trial met primary endpoint SOC: Standard of Care Elraglusib + GnP doubled 1 - year OS vs. GnP alone (p=0.0004) 2.5x increase in 1 - year OS in patients with liver metastases (p=0.0003) Elraglusib + SOC (GnP) improv
Slide 8: Greater Elraglusib Exposure Drives Improved OS Outcomes
7 Greater Elraglusib Exposure Drives Improved OS Outcomes Target Therapeutic IV Dose Identified Multivariable Cox Proportional Hazards Analysis Increased frequency of dosing could further improve OS benefit PK analyses showed patients exceeding exposure C avg of 210 ng/ml with significantly better o
Slide 9: Oral Tablet Provides Expedited Pathway to High Dose Exposure
8 Oral Tablet Provides Expedited Pathway to High Dose Exposure Increased frequency of dosing could further improve OS benefit Analysis demonstrates 9.3 mpk QW as Minimally Effective Dose (MED). ~85% of elraglusib 2QW patients vs ~60% QW patients achieve target exposure Oral dosing in models suggest
Slide 10: Elraglusib Tablet to Expand Portfolio of Blockbuster Indications
9 Two tablets could replace an IV infusion and increase overall exposure with daily dosing Nonclinical studies show >95% bioavailability, enabling higher dosing IND clearance received from FDA to initiate Ph1/2 study Potential first clinical candidate indications include: Elraglusib Tablet to Expand
Slide 11: Elraglusib in Rare Pediatric Cancers
Elraglusib in Rare Pediatric Cancers
Slide 12: EWS and NBL: Rare Diseases with High Unmet Need
11 EWS and NBL: Rare Diseases with High Unmet Need 1. Stahl M, Ranft A, Paulussen M, et al.: Risk of recurrence and survival after relapse in patients with Ewing sarcoma. Pediatr Blood Cancer 57 (4): 549 - 53, 2011 2. Van Mater and Wagner. Onco Targets Ther. 2019;12:2279 - 2288. 3. Bagatell R, DuBoi
Slide 13: Durable Responses in Heavily Pre-treated Ewing Sarcoma Patients
12 Durable Responses in Heavily Pre - treated Ewing Sarcoma Patients Phase 1 Solid Tumor Study (n=40): 9 elra monotherapy, 12 elra + irinotecan, 19 elra + cyclophosphamide/topotecan Elraglusib + cyclo/topo patients • 10/19 patients responded/achieved disease control • 12 EWS, 6 R/R patients responde
Slide 14: Nonclinical Data Support Further Development in Neuroblastoma
13 Nonclinical Data Support Further Development in Neuroblastoma • Addition of elraglusib to SOC chemoimmunotherapy led to markedly superior survival in independent nonclinical research studies • Data submitted for publication in peer review journal in 2Q26 9 - ING - 41: Scientific name for elraglus
Slide 15: Clinical Data Support Further Development in Neuroblastoma
14 Clinical Data Support Further Development in Neuroblastoma Background ~38% patients with advanced relapsed/refractory disease responded with stable disease or better in Phase 1 clinical study of elraglusib + chemotherapy Complete Response • Last line NBL patient with unfavorable molecular profile
Slide 16: Elraglusib Development Strategy and Timelines
15 Elraglusib Development Strategy and Timelines Develop Elraglusib Oral Tablet to expand portfolio • 2H 2026: Initiate Phase 1/2 trial to expand into additional high value / blockbuster indications Advance pathway to be the backbone of SOC in PDAC • Mid - 2026/2H 2026: Complete nonclinical research
Slide 17: Seasoned and Successful Leadership
16 Andrew Dorr, MD – VP, Clinical Development • Proven oncology drug development leader with senior roles in the development of multiple blockbuster therapies • COO (Salmedix), CMO (Isis/Ionis Pharmaceuticals), Medical Research Advisor (Eli Lilly), and former NCI leader • Extensive expertise in firs
Slide 18: Nasdaq Global Market: ACTU
Nasdaq Global Market: ACTU
Actuate Therapeutics — Investor Presentation (May 2026) on 6ix